Human U251 glioma cell proliferation is suppressed by HET0016 [N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine], a selective inhibitor of CYP4A

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 2, 2005, Pages 526-533

  Guo, Meng ^a   Roman, Richard J ^b   Falck, John R ^c   Edwards, Paul A ^a   Scicli, A Guillermo ^a,d  

^a HENRY FORD HOSPITAL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXYEICOSA 5,14 DIENOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID; ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; ARACHIDONIC ACID; CYTOCHROME P450 4A; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMAMIDE DERIVATIVE; HET 0016; ICOSANOID; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N HYDROXY N' (4 BUTYL 2 METHYLPHENYL)FORMAMIDINE; PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ALKANE 1-MONOOXYGENASE; AMIDINES; ANTINEOPLASTIC AGENTS; ARACHIDONIC ACID; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA FRAGMENTATION; ENZYME INHIBITORS; FLOW CYTOMETRY; GLIOMA; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; IN SITU NICK-END LABELING; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SIGNAL TRANSDUCTION; THYMIDINE;

EID: 27144552930     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.088567     Document Type: Article

References (31)

1. Alonso-Galicia M, Falck JR, Reddy KM, and Roman RJ (1999) 20-HETE agonists and antagonists in the renal circulation. Am J Physiol 277:F790-F796.
2. Amaral SL, Maier KG, Schippers DN, Roman RJ, and Greene AS (2003) CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. Am J Physiol 284:H1528-H1535.
3. Blagosklonny MV (2003) Apoptosis, proliferation, differentiation: in search of the order. Semin Cancer Biol 13:97-105.
4. Blagosklonny MV and Pardee AB (2002) The restriction point of the cell cycle. Cell Cycle 1:103-110.
5. Capdevila JH and Falck JR (2002) Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat 68-69:325-344.
6. Chen P, Guo M, Wygle D, Edwards PA, Falck JR, Roman RJ, and Scicli AG (2005) Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol 166:615-624.
7. Fleming I (2001) Cytochrome P450 and vascular homeostasis. Circ Res 89:753-762.
8. Gebremedhin D, Lange AR, Lowry TF, Taheri MR, Birks EK, Hudetz AG, Narayanan J, Falck JR, Okamoto H, Roman RJ, et al. (2000) Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res 87:60-65.
9. Green DR and Evan GI (2002) A matter of life and death. Cancer Cell 1:19-30.
10. Hoagland KM, Flasch AK, and Roman RJ (2003) Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 42:669-673.
11. Ito O and Roman RJ (1999) Regulation of P-450 4A activity in the glomerulus of the rat. Am J Physiol 276:R1749-R1757.
12. Jiang M, Mezentsev A, Kemp R, Byun K, Falck JR, Miano JM, Nasjletti A, Abraham NG, and Laniado-Schwartzman M (2004) Smooth muscle-specific expression of CYP4A1 induces endothelial sprouting in renal arterial microvessels. Circ Res 94:167-174.
13. Kohno M and Pouyssegur J (2003) Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Prog Cell Cycle Res 5:219-224.
14. Lin F, Rios A, Falck JR, Belosludtsev Y, and Schwartzman ML (1995) 20-Hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. Am J Physiol 269:F806-F816.
15. Miyata N, Taniguchi K, Seki T, Ishimoto T, Sato-Watanabe M, Yasuda Y, Doi M, Kametani S, Tomishima Y, Ueki T, et al. (2001) HET0016, a potent and selective inhibitor of 20-HETE-synthesizing enzyme. Br J Pharmacol 133:325-329.
16. Muthalif MM, Benter IF, Karzoun N, Fatima S, Harper J, Uddin MR, and Malik KU (1998) 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin- dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci USA 95:12701-12706.
17. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, et al. (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 15:3307-3318.
18. Nieder C, Schlegel J, Andratschke N, Thamm R, Grosu AL, and MollsM(2003) The role of growth factors in central nervous system tumours. Anticancer Res 23:1681-1686.
19. Parmentier JH, Lavrentyev EN, Falck JR, Capdevila JH, and Malik KU (2005) Evaluation of cytochrome P450 4 family as mediator of phospholipase D activation in aortic vascular smooth muscle cells. Life Sci 77:1015-1029.
20. Reiners JJ Jr, Clift R, and Mathieu P (1999) Suppression of cell cycle progression by flavonoids: dependence on the aryl hydrocarbon receptor. Carcinogenesis 20:1561-1566.
21. Rich JN and Bigner DD (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3:430-446.
22. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185.
23. Sacerdoti D, Gatta A, and McGiff JC (2003) Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat 72:51-71.
24. Sato M, Ishii T, Kobayashi-Matsunaga Y, Amada H, Taniguchi K, Miyata N, and Kameo K (2001) Discovery of a N′-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorg Med Chem Lett 11:2993-2995.
25. Scholler A, Hong NJ, Bischer P, and Reiners JJ Jr (1994) Short and long term effects of cytoskeleton-disrupting drugs on cytochrome P450 Cyp1a-1 induction in murine hepatoma 1c1c7 cells: suppression by the microtubule inhibitor nocodazole. Mol Pharmacol 45:944-954.
26. Sun CW, Falck JR, Harder DR, and Roman RJ (1999) Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension 33:414-418.
27. Uddin MR, Muthalif MM, Karzoun NA, Benter IF, and Malik KU (1998) Cytochrome P-450 metabolites mediate norepinephrine-induced mitogenic signaling. Hypertension 31:242-247.
28. Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, and Schwartzman ML (1998) Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 284:966-973.
29. Wang MH, Wang J, Chang HH, Zand BA, Jiang M, Nasjletti A, and Laniado-Schwartzman M (2003) Regulation of renal CYP4A expression and 20-HETE synthesis by nitric oxide in pregnant rats. Am J Physiol Renal Physiol 285:F295-302.
30. Yu M, Cambj-Sapunar L, Kehl F, Maier KG, Takeuchi K, Miyata N, Ishimoto T, Reddy LM, Falck JR, Gebremedhin D, et al. (2004) Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol 486:297-306.
31. Zhao X and Imig JD (2003) Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 4:73-84.